 This study found that individuals who received the BNT162B2 booster vaccine experienced fewer and less severe symptoms compared to unvaccinated or primed individuals. Additionally, these individuals also reported improved health-related quality of life and work productivity activity impairment. These findings suggest that the BNT162B2 booster may be effective in reducing the long-term effects of COVID-19.